Sherlock Biosciences is a diagnostics company using CRISPR and synthetic biology platforms to provide at-home molecular testing solutions.
Sherlock Biosciences, founded by Catalio Venture Partner Dr. Jim Collins, has engineered two pioneering technology platforms, called INSPECTR and SHERLOCK, that deliver diagnostic tests with the accuracy of PCR and the convenience and simplicity of antigen tests. By using CRISPR enzymes and synthetic biology, Sherlock’s products can detect DNA and RNA associated with a huge range of diseases. The simplicity of their products means tests can be done at home as well as in a low resource setting, and without the need for specialist knowledge or equipment to process samples or interpret results. Sherlock made history in 2020 when one of its products became the first FDA-authorized use of CRISPR technology; the company is positioned to transform the quality and patient experience of at-home diagnostics.